<DOC>
	<DOCNO>NCT01936909</DOCNO>
	<brief_summary>The RED-HART randomize double-blinded placebo-controlled study Anakinra ( IL-1 blocker ) patient recently decompensated heart failure determine safety efficacy term aerobic exercise capacity ventilatory efficiency measure cardiopulmonary exercise test .</brief_summary>
	<brief_title>Interleukin-1 Blockade Recently Decompensated Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>All 6 criterion need meet enrollment patient study 1 . Primary diagnosis hospitalization decompensated heart failure establish find admission 2 condition list : 1. dyspnea respiratory distress tachypnea rest minimal exertion ; 2. evidence elevate cardiac filling pressure pulmonary congestion ( least one condition must meet ) ; pulmonary congestion/edema physical exam OR chest XRay ; plasma Brain Natriuretic Peptide ( BNP ) level ≥200 pg/ml ; invasive measurement leave ventricular enddiastolic pressure &gt; 18 mmHg pulmonary artery occluding pressure ( wedge ) &gt; 16 mmHg . 2 . The patient prior documentation impair leave ventricular systolic function ( ejection fraction &lt; 50 % ) recent assessment image modality ( within 12 month ) . 3 . The patient clinically stable meet standard criterion hospital discharge document 3 condition list : 1. absence dyspnea pulmonary congestion/distress rest ; 2. absence pit edema low extremity , region ; 3. stable hemodynamic parameter ( blood pressure , heart rate ) . 4 . The patient age ≥21 year old , willing able provide write informed consent . 5 . The patient willing able comply protocol ( i.e . self administration treatment , exercise protocol ) . 6 . The patient screen plasma Creactive protein level &gt; 2 mg/L . Exclusion Criteria Subjects eligible meet follow 15 exclusion criterion . 1 . The primary diagnosis admission NOT decompensated heart failure , include diagnosis acute coronary syndrome , hypertensive urgency/emergency , tachy bradyarrhythmias . 2 . Concomitant clinically significant comorbidities would interfere execution interpretation study include limited acute coronary syndrome , uncontrolled hypertension orthostatic hypotension , tachy bradyarrhythmias , acute chronic pulmonary disease neuromuscular disorder affect respiration . 3 . Recent ( previous 3 month ) plan cardiac resynchronization therapy ( CRT ) , coronary artery revascularization procedure , heart valve surgery . 4 . Previous planned implantation leave ventricular assist device hearttransplant . 5 . Chronic use intravenous inotropes . 6 . Recent ( &lt; 14 day ) use immunosuppressive antiinflammatory drug ( include NonSteroidal AntiInflammatory Drugs [ NSAIDs ] ) . 7 . Chronic inflammatory disorder ( include limit rheumatoid arthritis , systemic lupus erythematosus ) . 8 . Active infection ( type ) ; 9 . Chronic/recurrent infectious disease ( include Hepatitis B virus [ HBV ] , Hepatitis C virus [ HCV ] , HIV/AIDS ) . 10 . Prior ( within past 10 year ) current malignancy . 11 . Any comorbidity limit survival ability complete study . 12 . End stage kidney disease require renal replacement therapy . 13 . Neutropenia ( &lt; 2,000/mm3 ) Thrombocytopenia ( &lt; 50,000/mm3 ) . 14 . Pregnancy . 15 . Angina , arrhythmia , electrocardiograph ( ECG ) change limit maximum exertion cardiopulmonary exercise testing obtain baseline testing .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>